巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

XTL Biopharmaceuticals Ltd

XTLB
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・XTL Biopharmaceuticals Ltd - 延遲價格・最後更新於 14/01 12:15
最高位
2.920
最低位
2.910
開市價
--
前收市價
2.960
成交量(千)
0.11
成交額(百萬)
0.00
買入
--
賣出
--
每手股數
--
市值(百萬)
15.75
市盈率
--
息率
--
差價
--
52週高低
6.690 - 2.560
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
XTL Biopharmaceuticals Ltd
證券代碼
XTLB.US
所屬板塊
Biotechnology
公司業務
XTL Biopharmaceuticals Ltd is engaged in the field of healthcare. It is a pharmaceutical manufacturer, with a focus on acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
發行量
5142057
公司總部
5 Badner Street
公司網址
http://www.xtlbio.com
公司電郵
info@xtlbio.com
公司電話
+972 36116600
暫無內容

關於

XTL Biopharmaceuticals Ltd(XTLB.US)所屬的行業板塊為Biotechnology。
XTL Biopharmaceuticals Ltd is engaged in the field of healthcare. It is a pharmaceutical manufacturer, with a focus on acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
詳細公司背景可參考: http://www.xtlbio.com